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a b s t r a c t
Ten years ago, the ﬁrst public proteomics repositories became available online. This anniver-
sary is therefore an excellent occasion to look back on the past decade and evaluate what
has changed in this time period. At the same time however, one should also dare to look
forward, and therefore prepare for the next 10 years of proteomics data sharing.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
The ﬁrst published efforts at collecting and disseminating
online proteomics data are traceable to 2004, with a report
by Prince et al. [1] on the one hand, and the original Global
Proteome Machine DataBase (GPMDB) publication by Craig
et al. [2] on the other hand. It is worth considering the dif-
ferences between these two efforts, as the former was aimed
at a generic dissemination platform that held only high-level
meta-information about the available data in a queryable
format, while the latter provided a full online data ecosystem,
complete with an integrated search engine (X!Tandem [3]) and
a fully queryable data structure that captured the details of
each spectrum and peptide-to-spectrum match (PSM). A sim-
ilar concept to the GPMDB was also found in the PeptideAtlas
Abbreviations: PSM, peptide-to-spectrum match; PTM, post-translational modiﬁcations.
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system published shortly afterwards by Deseire et al. [4],
building upon the Trans Proteomic Pipeline as a common
reprocessing back-end for all contained mass spectrometry
data [5]. Simultaneously, the Proteomics IDEntiﬁcations
(PRIDE) database was published as a bona ﬁde repository for
mass spectrometry based proteomics data [6], similar in basic
concept to the system proposed by Prince et al., but with
the important extension that PRIDE captured all data in an
experiment in a fully structured and queryable form. GPMDB,
PeptideAtlas and PRIDE are still fully operational today, and
the latter two have been founding members of the unifying
ProteomeXchange consortium [7]. In the 10 years that have
passed since the original publication of these resources, many
http://dx.doi.org/10.1016/j.euprot.2015.07.014
2212-9685/© 2015 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1 – Evolution of tissue metadata and PTM data annotation in PRIDE over the past 10 years. Plots are based on public
data submitted to PRIDE in each year from 2005 until 2015 (both inclusive). (a) Availability of tissue metadata information in
PRIDE over the past 10 years. Number of experiments with available tissue information are shown at left, while number of
experiments without this information are shown at right. (b) Availability of PTM annotations on identiﬁcations in PRIDE
over past 10 years. Number of experiments with available PTM information are shown at left, number of experiments
without this information are shown at right.
things have clearly evolved, and this Decennial of public pro-
teomics data sharing is therefore a good moment to look
back at what has changed in the ﬁeld, and what has not. The
ﬁndings also allow us to make some clear recommendations
for the next 10 years of proteomics data sharing.
One of the most important developments in the past 10
years of public proteomics data sharing is certainly the devel-
opment of numerous community standards for the various
proteomics data types [8–11], coupled to minimal reporting
guidelines that are all linked to the ﬂagship Minimal Informa-
tion About a Proteomics Experiment (MIAPE) standard [12]. In
principle, these combined developments should have created
a common minimal level of data formatting, and metadata
annotation for public proteomics data. Unfortunately, when
we consider the availability of tissue of origin metadata in
PRIDE over the past 10 years as retrieved by the PRIDE web
service [13], we can see that it took until 2013 before a trend
changewas observed in the relative availability of tissue anno-
tation (Fig. 1a). Intriguingly, the main cause for the trend
reversal is probably manual curatorial efforts by the PRIDE
submissions team [14] (helped in no small part by the PRIDE
Inspector software and its built-in quality control plots [15])
rather than the availability of submission software. Indeed,
in 2009 the PRIDE Converter application [16] made submis-
sion from many search engines much easier thanks to a
wizard-like interface, while a direct coupling to the Ontology
Lookup Service (OLS) [17] allowed easier metadata annotation
[18], but this development did not affect the relative abun-
dance of experiments with missing annotation at the tissue
level. Interestingly, the effect of PRIDE Converter on metadata
can be spotted quite easily when we consider the reporting
of detected post-translational modiﬁcations (PTMs) in PRIDE
(Fig. 1b), as the number of annotated PTMs grows much more
sharply than the number of unknown PTMs. The main rea-
son for the relative success of conversion software here is
that PTM annotation can be extracted automatically from the
search engine output, thus eliminating the need for active
user intervention. Even here however, the effect of stepped-up
manual curation since 2013 is prominently visible as missing
PTM annotation is almost entirely prevented. A similar pic-
ture about emerges when we consider the metadata about
the instrument used in the analysis. For the sake of clarity, all
reported instruments were grouped according to their mass
analyzer types for MS and MS/MS analysis (Fig. 2). Some note-
worthy trends are the emergence and subsequent dominance
of the orbitrap family of mass spectrometers in 2007 [19], and
the availability of fastMS/MS analysis in an orbitrap since 2012
[20]. Yet themost striking evolution is the overwhelming num-
ber of unannotated instruments, which here too declines from
2013 onwards.
It is obvious that adherence to the original MIAPE guide-
lines over the past 10 years has been haphazard at best, and
that manual veriﬁcation and active enforcement seems the
most effective strategy to ensure compliance. This is highly
regrettable because it saps valuable time and effort away
from the repository’s limited core staff, and because solu-
tions already have been built that can automatically examine
data sets for sufﬁcient and semantically correct metadata
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Fig. 2 – Evolution of the instrument metadata annotation in PRIDE over past 10 years. Plots are based on public data
submitted to PRIDE as ‘complete submissions’ in each year from 2005 until 2015 (both inclusive). Instruments have been
grouped based on their employed mass analyzers; if two mass analyzers are mentioned, ﬁrst one is used for the precursor
mass measurement, while second one is used for fragment ion mass measurement.
annotation [21] (http://www.psidev.info/validator) at the
server side, while web interfaces have been developed where
users could generate complete MIAPE-compliant reporting
[22]. Due to a lack of use, however, the latter service has fallen
into disrepair. More work is thus needed to bridge the gap
between the need to thoroughly annotate data and the con-
venience of the actual annotation process. The responsibility
in bridging this gap is ultimately shared between data gen-
erators and bioinformaticians, where the former should take
into account that properly sharing data can never be a com-
pletely trivial task, while the latter should endeavor to build
ever better and more intuitive tools for data annotation that
are tailored to the convenience of the data producer.
However, it is also clear that a vast amount, and great diver-
sity of data has been collected in PRIDE over the past decade.
Fig. 3 shows the 10 species with the most associated data
sets, along with all other species, and the number of data sets
with unknown species. Human samples contribute the clear
majority of all data, followed at some distance by other model
organisms. However, the enormous breadth of species cover-
age is implicit in the very sizable amount of data in the ‘other’
category. Also of interest is the small amount of data setswith-
out species annotation (‘unknown’), and the elimination of
this category after the stepped-up curatorial intervention in
2013.
The acquired data also show an evolution that tracks
the development of novel instruments. This is illustrated
by an analysis of the reported mass accuracies for the PSMs
in PRIDE by the pride-asap pipeline [23], which reports on
the maximal precursor and fragment ion mass accuracies
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Fig. 3 – Species spread of PRIDE data sets. Plots are based on public data submitted to PRIDE as ‘complete submissions’ in
each year from 2005 until 2015 (both inclusive). Relative contribution to total number of data sets in PRIDE across all
considered years is shown. Ten species with the most associated data sets are separately highlighted, while all other
species are grouped in the ‘other’ category. Also shown are data sets without species annotation, in the ‘unknown’ category.
per experiment after removal of outliers (mass errors with a
z-score larger than three were removed). As Fig. 4 illustrates,
the precursor mass accuracy has sharply increased since 2007
as more accurate mass analyzers became widely available,
while precursor mass accuracies have only more gradually
decreased over time.
At the end of the ﬁrst 10 years of proteomics data shar-
ing, an unexpected ﬁrst ﬁnding is that, despite ample progress
on the infrastructure front, it most likely took (semi-)manual
veriﬁcation and assistance to ensure that minimal meta-
data annotation could be made available for submitted data
sets. While this curatorial effort has thus apparently rectiﬁed
the situation, it must be pointed out that this is a decid-
edly suboptimal situation as such manual intervention is not
readily scalable, and should be replaced by more convenient
possibilities for a priori submitter self-evaluation of meta-
data completeness, provided by a much more widespread
development and subsequent adoption of automated and con-
venient software tools that can ﬂag and help remedy any
issues.
A second ﬁnding is that improved instruments have
contributed greatly to more accurate mass accuracies, ﬁrst
only for precursor masses, but increasingly also for frag-
ment ion masses. It is however, striking to see how
quickly these novel instruments are adopted by the com-
munity, which demonstrates that a willingness and ability
to invest in the latest mass spectrometers is an impor-
tant prerequisite to remain at the forefront of this ﬁeld.
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Fig. 4 – Evolution of precursor and fragment ion mass errors in PRIDE. Plots are based on public data submitted to PRIDE as
‘complete submissions’ in each year from 2006 until 2014 (both inclusive). Limited availability of data from 2005, and
incomplete data from 2015 led to the exclusions of these 2 years. (a) Evolution of measured precursor mass error over time.
(b) Evolution of measured fragment ion mass error over time.
Moreover, this technology-driven character of the ﬁeld
is likely to be carried forward in the next decade as
well.
A highly promising and very interesting development for
the next 10 years of public proteomics data centers around the
increasing importance of quality control metrics [24] and their
dissemination along with publicly available data sets [25,26].
The provision of the ﬁrst suitable tools [27–31] and standards
[32] have already provided the necessary infrastructure to put
such automated quality control and assessment in place, and
it would most certainly beneﬁt the ﬁeld to include the provi-
sion of these metrics in the minimal reporting requirements,
or generate them automatically for any data set in the public
domain.
Finally, one of the most promising developments for the
coming decade centers on the ability to reuse these data
in orthogonal ways. This ability, supported by end-user ori-
ented tools such as PeptideShaker [33], opens up highly
interesting new avenues for data exploration, ranging from
meta-analyses [34], over the collation of compendia [35,36], to
novel discoveries [37,38]. Indeed, the ﬁrst 10 years of public
proteomics data may have already been exciting, but the next
10 years are poised to be even more exhilarating!Conﬂict of
interest
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